病前残疾或痴呆的急性缺血性卒中患者的血管内治疗与溶栓治疗:美国心脏协会/美国卒中协会科学声明
该科学声明回顾了病前残疾或痴呆的急性缺血性卒中患者接受溶栓和血管内治疗的文献。观察性研究提示此类患者血管内治疗的安全性可比,且治疗后有可能保留病前残疾水平,但需更高质量注册研究和临床试验验证。声明提出指导临床医生、临床科学家和决策者的原则。
要点
- 病前残疾或痴呆患者常被排除在溶栓和血管内治疗的随机对照试验之外。
- 观察性研究提示血管内治疗在此类患者中安全性可比,溶栓有类似数据。
- 此类患者治疗后有可能保留病前残疾水平,但需更高质量研究验证。
核心结论
- 通过临床实践中务实透明的决策与积极追求高质量研究相结合,可朝着更包容的以患者为中心的照护模式努力。
研究设计与样本
- 美国心脏协会/美国卒中协会科学声明,回顾病前残疾或痴呆的急性缺血性卒中患者接受急性卒中治疗的文献。
主要发现
- 近期临床流行病学研究显示病前残疾或痴呆的概念和测量存在挑战,且普通卒中人群中相当比例属于此范畴,面临被排除治疗的风险。
- 此类研究还阐明卒中后残疾每增加一个等级带来的不良长期临床和健康经济后果,强调寻找策略减轻额外残疾的重要性。
- 若干观察性研究(病例系列和注册研究)表明病前残疾或痴呆患者与无此情况患者血管内治疗的安全性可比,补充了溶栓的类似数据。
- 这些数据还提示此类患者治疗后有可能保留病前残疾水平,尽管其总体预后通常更差,但此点仍需更高质量注册研究和临床试验验证。
临床怎么用
- 原文未据此给出推荐。
局限性
- 此类患者通常被排除在溶栓和血管内治疗的随机对照试验之外。
- 保留病前残疾水平的潜力仍需更高质量注册研究和临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with premorbid disability or dementia have generally been excluded from randomized controlled trials of reperfusion therapies such as thrombolysis and endovascular therapy for acute ischemic stroke. Consequently, stroke physicians face treatment dilemmas in caring for such patients. In this scientific statement, we review the literature on acute ischemic stroke in patients with premorbid disability or dementia and propose principles to guide clinicians, clinician-scientists, and policymakers on the use of acute stroke therapies in these populations. Recent clinical-epidemiological studies have demonstrated challenges in our concept and measurement of premorbid disability or dementia while highlighting the significant proportion of the general stroke population that falls under this umbrella, risking exclusion from therapies. Such studies have also helped clarify the adverse long-term clinical and health economic consequences with each increment of additional poststroke disability in these patients, underscoring the importance of finding strategies to mitigate such additional disability. Several observational studies, both case series and registry-based studies, have helped demonstrate the comparable safety of endovascular therapy in patients with premorbid disability or dementia and in those without, complementing similar data on thrombolysis. These data also suggest that such patients have a substantial potential to retain their prestroke level of disability when treated, despite their generally worse prognosis overall, although this remains to be validated in higher-quality registries and clinical trials. By pairing pragmatic and transparent decision-making in clinical practice with an active pursuit of high-quality research, we can work toward a more inclusive paradigm of patient-centered care for this often-neglected patient population.
引用
- Ganesh A, Fraser JF, Gordon Perue GL, et al. Endovascular Treatment and Thrombolysis for Acute Ischemic Stroke in Patients With Premorbid Disability or Dementia: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2022. PMID: 35343235. doi:10.1161/STR.0000000000000406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。